Merck & Co. Partners with Themis on Measles Virus Vector-Based Vaccines - Genetic Engineering & Biotechnology News

Merck & Co. Partners with Themis on Measles Virus Vector-Based Vaccines  Genetic Engineering & Biotechnology News

Merck & Co. will partner with Themis Bioscience to develop vaccine candidates based on Themis' measles virus vector-based platform, through the Austrian ...